Agile BioFoundry的动态

?????????????? ??/?? ?????????????????? ???????????????? ?????? ???????????????????? ???????? With the rise of #GenAI and #LLMs, there is a lot of chatter wrt manual v/s automated curation vis-à-vis precision v/s pace. But does manual curation really mean dotting the i's and crossing the t's but very slow paced, or can automated curation maintain accuracy alongside speed and stability??? Find out in our blog here-https://lnkd.in/gmcnqrVC #manualcuration #biotech

Who else is going to the AI for Bioscience (ai4b.io) conference in Delft in April? I am really looking forward to the event! I hope to be allowed to present some work on reward functions for experimental design optimization algorithms. #artificialintelligence #biotech #machinelearning #experimentaldesign #drugdevelopment

Explore how biotechnology and computational technologies intersect with D Young & Co LLP on 13 March at 1pm UTC! Experts will be discussing effective strategies for using AI-derived data in patent applications. (https://lnkd.in/evWNGbXM) ? During the masterclass, experts will guide you through the evolving landscape of techbio innovation and help you understand whether a successful patent application in this field still depends on traditional wet-lab data or if the focus should be on AI-derived data. Speakers: Robbie Berryman, Partner, D Young & Co LLP Jennifer O'Farrell, Partner, D Young & Co LLP ? #Patents?#Biotech?#AI?#LegalTech

I recently delved into?"The Coming Wave"?by Mustafa Suleyman, a book that offers a sweeping vision of the future shaped by advanced technologies like AI and biotechnology. While the book is undoubtedly thought-provoking, it also left me with mixed feelings. Read more on :https://lnkd.in/gZpNzJAy

Laboratory News Issue 2 2024 is out now! ???? Check out the latest happenings in the laboratory world. ?? Russ Swan talks about publishing despairs and how commercial priorities are killing the usefulness of web platforms. ?? Enhancing biomaterials' water resistance through chemical modification increases their potential to replace emissions-heavy materials and provide a major reduction in manufacturing CO2. Dr. Jack Andrew explains how start-up Cellexcel is working with funders and academia to accelerate commercialisation of the technology ?? Managing director of show organisers UK Industry Events Ltd, Ian Stone discusses how he seeks to balance laboratory R&D with scaled-up manufacturing to present a holistic view of the chemicals sector and its cutting edge ?? Al has proven its worth as a research tool and now it's time to tap its potential for clinical trials, argues Tero Laulajainen, Vice President - Head Global Clinical Science and Operations at UCB - A global biopharma company, inspired by the needs of people living with severe diseases. ?? Bryan Hill, Vice President Digital Health & Innovation, CTO - Life Sciences at Cognizant talks about AI's capability of refining content and analysing data. And a lot more! Click here to read the latest from the field of Lab tech ?? https://lnkd.in/g9w9Ycdd #LabNews #science #digitalmagazine #research #ai #labmanagement

People often ask about the future of foundational models in biology—will a single model dominate, or will we see a proliferation of specialized models? My answer is, we'll have both. #GenAI is set to revolutionize biotech in profound ways, creating room for both expansive, general-purpose models and highly specialized niche models tailored to unique applications. At Converge Bio, we’re making foundational biological language models accessible and usable for the biotech industry. Follow us to learn more about how we're driving innovation forward!

We recently published a report on 'The Brave New World Of Synthetic Biology,' which explores the impact of new technologies on business, society and people. Synthetic Biology – SynBio for short – is a multi-disciplinary field of innovation focused on the analysis and manipulation of biological systems. SynBio has the potential to be disruptive across many industry sectors — not just life sciences, food and agriculture, but also industrial, chemicals, manufacturing, consumer goods, energy, and IT. Based on extensive research, plus interviews with global experts, this new report discusses how businesses should prepare for the SynBio future. You can read it here: https://lnkd.in/gHNjdwVZ #SynBio #AI

Did you know that X-Chem is a contributor to the The Structural Genomics Consortium (SGC)'s #Target2035 initiative, an open science global movement focusing on the creation of chemical and biological tools to study human proteins and inform drug discovery? As a pioneer of DNA-encoded chemical library technology, we are generating quality datasets from DEL screens of individual targets, curating the datasets so that they are compatible with machine learning, and through the SGC, posting the data to the public portal “AIRCHECK” for researchers around the world to access and build models with. Target2035 aims to develop a pharmacological modulator for every protein in the human proteome by 2035. While still in its early phase, AIRCHECK is now available: https://aircheck.ai/ #DataScience #MachineLearning #Sustainability #OpenAccess

For the first day of #AGBT the main question on people minds is the future of the sequencing market. Illumina is clearly the entrenched leader. Ultima Genomics is aiming to compete on the high throughput level against the NovaSeq, while Element Biosciences is pushing against the NextSeq. Both companies are working on very high quality scores of Q60 which is way higher than the standard Q30. These companies are attacking the high quality scores from different angles, but they are a combination of chemistry and informatics. Ultima seems to have overcome their homopolymer issues by using AI and training. It is interesting to think it Ion Torrent by Life Technologies could have properly addressed their homopolymer issues using the compute that is available in 2024 as compared to what they had 10 years ago. For Element, one of the keys to high quality seems to be excluding part of read 2. From analysis of control samples, Element realized that a lot of their errors occur at the beginning of read 2. By simply starting recording the read 2 reads only from base 10, they we able to greatly boost their quality scores. This is a surprisingly simple tweak to improve read quality.

???Inside Vector Bioscience: TechTales of Innovation??? Vector Bioscience is formed by a #team of scientists and entrepreneurs with a big mission: to transform drug delivery. How? With our nanoshuttle technology that allows us to make drug delivery more #effective, #targeted and #stable.? This clip showcases our precision technology made of tiny Lego-like block with huge porosities. Using machine learning we select and create the best #nanoshuttle for each API and indication. Join us on this journey to revolutionize healthcare! Stay tuned for more #TechTale clips. ??????#VectorBioscience #DrugDelivery #Innovation #TechTales #HealthcareRevolution???????